Activities of Azithromycin and Amphotericin B against Naegleria fowleri In Vitro and in a Mouse Model of Primary Amebic Meningoencephalitis

Shannon M. Goswick and George M. Brenner*

Department of Pharmacology, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma 74107-1898

Inhalation of fresh water containing the free-living ameba Naegleria fowleri may lead to a potentially fatal infection known as primary amebic meningoencephalitis. Amphotericin B is the only agent with established clinical efficacy in the treatment of primary amebic meningoencephalitis in humans, but therapy with this drug is often associated with adverse effects on the kidneys and other organs, and not all persons treated with amphotericin B have survived. We investigated the in vitro activity and in vivo efficacy of newer therapeutic agents in an attempt to identify other useful agents for treating primary amebic meningoencephalitis. Azithromycin has shown in vitro activity against Acanthamoeba spp. and in vivo activity against experimental toxoplasmosis. In our study, the MIC of azithromycin against N. fowleri was 13.4 μM (10 μg/ml), which was 123 times greater than the MIC of amphotericin B, which was 0.108 μM (0.1 μg/ml). Azithromycin protected 100% of mice infected with N. fowleri at a dose of 75 mg/kg/day for 5 days, whereas amphotericin B protected only 50% of mice at a dose of 7.5 mg/kg/day for 5 days, and all control mice died during the 28-day observation period. We conclude that azithromycin has both in vitro and in vivo activity versus N. fowleri and may be a useful addition to therapy for primary amebic meningoencephalitis.

Materials and Methods

Amebae and cultivation. The Lee (M67) strain of N. fowleri used in this study was originally isolated from a 15-year-old female who died from primary amebic meningoencephalitis in 1968 (12) and has been maintained by 67 passages in mice to retain maximum virulence. The Lee (M67) strain was cultured axenically without agitation in Mix medium (12). Stock cultures of N. fowleri were maintained at 37°C in 25-cm² polystyrene culture flasks containing 10 ml of medium.

Therapeutic agents. Amphotericin B aqueous solution, 250 μg/ml (Sigma-Aldrich Inc., St. Louis, Mo.), was diluted with sterile deionized water to obtain the final concentrations used for in vitro studies. For in vivo studies, amphotericin B powder, consisting of 45% amphotericin B, 35% deoxycholic acid sodium, and 20% sodium phosphate (Sigma-Aldrich Inc.), was dissolved in sterile deionized water to provide the amphotericin B concentrations needed to administer the indicated doses to mice. Azithromycin for injection (Zithromax; Pfizer Inc., New York, N.Y.), consisting of powdered azithromycin dihydrate, was dissolved in viral medium containing 50% fetal bovine serum and the final concentrations used for in vitro studies. For in vivo studies, azithromycin was dissolved in sterile deionized water to provide the indicated doses to mice. Stock cultures of Acanthamoeba were grown axenically without agitation in spore medium (North Carolina State University, Raleigh, N.C.).

Received 5 September 2002/Returned for modification 11 October 2002/Accepted 31 October 2002

* Corresponding author. Mailing address: Department of Pharmacology, Oklahoma State University Center for Health Sciences, 1111 W. 17th St., Tulsa, OK 74107-1898. Phone: (918) 561-8248. Fax: (918) 561-8414. E-mail: gmbrenner@chs.okstate.edu.

524
in and diluted with sterile deionized water to provide the concentrations and doses employed in this study.

**In vitro studies.** For each drug study, 30 ml of Mix medium was inoculated with 10^5 ameba/ml from 72-h stock cultures. An aliquot of diluted amphotericin B or azithromycin solution was added to experimental flasks to obtain the required drug concentrations, while control flasks received the same 0.12-ml volume of deionized water. Agents were tested at three concentrations, with each concentration tested in triplicate. Amphotericin B was serially diluted to provide final concentrations of 0.01, 0.1, and 1 µg/ml, while azithromycin was diluted to final concentrations of 1, 10, and 100 µg/ml.

The flask containing ameba and an experimental agent were vortex shaken, and 10-ml aliquots were distributed to three culture flasks that were incubated at 37°C. Cell growth was determined daily for a period of 96 h and then again at 168 h with a Coulter counter (model ZM, Coulter Electronics, Inc., Hialeah, Fla.). A 0.2-ml aliquot of each cell suspension was added to 9.8 ml of electrolyte solution consisting of 0.5% (vol/vol) formalin and 0.4% (wt/vol) NaCl in deionized water. Cuvettes were vortex shaken to separate cell aggregates and then read within 5 min. Four successive counts were obtained for each cuvette. The most deviant count for each cuvette was excluded, and the mean of the remaining nine counts (three flasks of three counts each) was determined, and ameba growth was expressed as amebas per milliliter. Ameba concentrations were compared with Student's t test to determine whether differences between control and treated groups were significant. The MIC of each agent was defined as the lowest concentration that significantly (P < 0.05) inhibited ameba growth compared to control cultures throughout the 7-day culture period as determined by Student's t test.

**In vivo studies: cell harvesting and inoculation.** Amebae were harvested for mouse inoculations after 72 h of culture in Mix medium at 37°C. The ameba were centrifuged at 2,000 × g for 10 min, washed, and resuspended in Page saline to provide a final concentration of 2 × 10^6 ameba/ml. Male 21-day-old CD-1 mice weighing approximately 23 g (Charles River Laboratories, Inc., Wilmington, Mass.) were used in all in vivo experiments. Prior to experimentation, mice were housed in plastic cages for 3 days and given free access to food and water. Mice were inoculated by intranasal instillation of 10 ml of Page saline containing 2 × 10^4 ameba into a single naris under isoflurane anesthesia (AETrane; Baxter Caribe Inc., Deerfield, Ill.). All animal studies were conducted in accordance with standard animal experimentation guidelines and with the approval of the Animal Care and Use Committee at the Oklahoma State University Center for Health Sciences.

**Treatment of experimental amebic meningoencephalitis.** Experimental drug treatments began 72 h after inoculation of ameba and continued once daily for 5 days. For each set of experiments, 40 mice were randomly divided into four groups of 10 mice, with each group receiving a different treatment. The control group received daily 0.1-ml intraperitoneal injections of 0.9% sodium chloride injection (Abbott Laboratories, Chicago, Ill.). The treated groups received 0.1-ml intraperitoneal injections containing the active drug in sufficient concentration to provide the specified dosages of amphotericin B (2.5 or 7.5 µg/kg) or azithromycin (25 or 75 µg/kg). Doses represent the quantity of amphotericin B or azithromycin base administered to mice per kilogram of body weight.

**Mortality and mean time to death.** Mice were held for 28 days after inoculation, and the cumulative percent dead was recorded on a daily basis. The mean time to death was also determined for each treatment group. In order to verify the cause of death, brain tissue from dead mice was cultured for ameba with 10^4 ameba/ml from 72-h stock cultures. An aliquot of diluted amphotericin B or azithromycin solution was added to experimental flasks to obtain the concentrations of amphotericin B on the growth of the Lee (M67) strain of N. fowleri in vitro was 13.4 µM (10 µg/ml). Thus, amphotericin B was about 123 times more potent on a molar basis than azithromycin in vitro. In contrast, azithromycin was more effective than amphotericin B in an experimental model of primary amebic meningocencephalitis.
meningoencephalitis despite its lower in vitro MIC. Azithromycin protected 100% of mice at a dose of 75 mg/kg/day, whereas amphotericin B protected only 50% of mice at a dose of 7.5 mg/kg/day. A lower azithromycin dose of 25 mg/kg/day protected 40% of mice with primary amebic meningoencephalitis and significantly increased the mean time to death.

Amphotericin B is the most potent agent showing activity against N. fowleri, with a MIC ranging from 0.018 to 1.0 μg/ml in various studies (5, 7, 8, 13, 17, 20, 21). The MIC of amphotericin B in our studies (0.1 μg/ml) is close to the median of values reported by other investigators. We found that azithromycin was more effective than amphotericin B in experimental primary amebic meningoencephalitis despite having an MIC that was approximately 123 times greater than that of amphotericin B. The greater in vivo efficacy of azithromycin may be related to the unique pharmacokinetics of this drug, which

**FIG. 1. Effect of amphotericin B (A) and azithromycin (B) on in vitro growth of the Lee (M67) strain of N. fowleri grown in Mix medium at 37°C. Values are means ± standard errors of two experiments performed in triplicate. Error bars that are not visible are smaller than the symbols. Student’s t test was used to compare means for treated and control samples at 48 and 168 h. **, significantly different from controls, P < 0.01.**
include a long elimination half-life and high tissue levels (10). Amphotericin B exhibits poor penetration of the blood-brain barrier, whereas azithromycin was widely distributed into human brain tissue following systemic administration to humans (11).

The doses of azithromycin and amphotericin B used in this study were the same doses used by other investigators in experimental primary amebic meningoencephalitis (amphotericin B) or toxoplasmosis (azithromycin). The amphotericin B doses used in mice (2.5 and 7.5 mg/kg/day) are larger than the doses used in the treatment of primary amebic meningoencephalitis in humans (1 to 1.5 mg/kg/day), as reported by John (12). However, Carter (5) stated that the high dose of amphotericin B (7.5 mg/kg) is lower than that required to protect mice from many fungal infections. Based on body surface area rather than weight, this dose is comparable to that customarily used in humans, and the level of amphotericin B in mouse serum with this dose (1.2 μg/ml) is much the same as found in

FIG. 2. Survival of mice after inoculation with $2 \times 10^4$ N. fowleri, followed by treatment with amphotericin B (A) or azithromycin (B) injected once daily on days 4 to 8 after infection. Control mice received sterile saline. There were 10 animals per group.
human subjects receiving the usual intravenous doses (5). Carter also showed that 100% of mice survived treatment with amphotericin B at 7.5 mg/kg/day for 10 days. Nevertheless, the high doses of amphotericin B employed in our study may potentially cause kidney toxicity or even contribute to lethality in mice with experimental primary amebic meningoencephalitis.

Likewise, the doses of azithromycin employed in experimental toxoplasmosis (25 to 200 mg/kg) are larger than those required for the successful treatment of human infections. It was reported that 100% of mice with experimental toxoplasmosis survived treatment with 200 mg of azithromycin per kg for 10 days (3). We did not observe any obvious toxicity in mice treated with azithromycin at 75 mg/kg for 5 days.

The protocol used in our mouse model of primary amebic meningoencephalitis employed treatments that began 72 h after inoculation of mice with Naegleria fowleri, whereas most investigators began drug therapy prior to or immediately after inoculation (5, 9, 24). We believe that our protocol more closely resembles the clinical setting, in which patients do not present with severe symptoms until several days after exposure to N. fowleri. This model is therefore more likely to indicate which therapeutic agents might be effective against primary amebic meningoencephalitis in a clinical setting. The only other study of delayed treatment of experimental primary amebic meningoencephalitis found that 37.5% of animals survived after treatment with amphotericin B at 2.5 mg/kg/day for 7 days, which is similar to the 30% survival obtained in our study (23).

Further studies are needed to determine whether azithromycin demonstrates additive, synergistic, or antagonistic effects in combination with amphotericin B in mouse models. Little is known about the mechanisms of action of amphotericin B or other drugs against N. fowleri. Azithromycin inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit and blocking peptide bond formation and translocation, but its mechanisms of action in Acanthamoeba, Naegleria, and Toxoplasma spp. have not been identified and deserve investigation.

ACKNOWLEDGMENT

We gratefully acknowledge David T. John for providing helpful advice and laboratory facilities.

REFERENCES